Clinical Trial Update: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A clinical study evaluating the safety and efficacy of ETX101, an AAV9-delivered gene therapy, in children with SCN1A-positive Dravet syndrome; Phase 1/2 trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dravet Syndrome

Drugs mentioned

• ETX101

Snippet

Sponsor: Encoded Therapeutics | Conditions: Dravet Syndrome | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING